<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48693">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472314</url>
  </required_header>
  <id_info>
    <org_study_id>2014-193</org_study_id>
    <nct_id>NCT02472314</nct_id>
  </id_info>
  <brief_title>Exparel for Postoperative Pain Management in Shoulder Surgery</brief_title>
  <official_title>A Novel Application of Exparel for Postoperative Pain Management in Shoulder Arthroplasty and Humerus Fracture Fixation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of liposomal Bupivacaine infiltration
      into the shoulder to continues nerve block with Bupivacaine on postoperative pain control
      and functional outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      liposomal bupivacaine analgesia will provide improved postoperative pain control, reduction
      in amount of opioid supplementation, decreased complications and faster return to function
      compared to current standard of care pain management for patients undergoing shoulder
      arthroplasty and shoulder surgery for proximal humerus fractures.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of analgesia</measure>
    <time_frame>30 days</time_frame>
    <description>Quality of analgesia as measured by numerical rating scores for pain (active and at rest) as (0=no pain, 10= worst pain) every two hours for the initial 36 hours, then on day2, day7 and day30 postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to discharge home</measure>
    <time_frame>72 hours</time_frame>
    <description>Hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to work</measure>
    <time_frame>2 weeks and 6 weeks post-operatively</time_frame>
    <description>Resumption of work or normal activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post operative American Shoulder and Elbow surgeons (ASES)</measure>
    <time_frame>2 weeks, 6 weeks, 3 months, 6 months and one year</time_frame>
    <description>Functional assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective shoulder value (SSV)</measure>
    <time_frame>2 weeks, 6 weeks, 3 months, 6 months and one year</time_frame>
    <description>Functional assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constant score</measure>
    <time_frame>2 weeks, 6 weeks, 3 months, 6 months and one year</time_frame>
    <description>Functional assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of nerve injury</measure>
    <time_frame>During hospital stay and at 2 weeks and 6 weeks post-operatively</time_frame>
    <description>Neuropraxia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post operative opioid consumption</measure>
    <time_frame>During hospital stay and at 2 weeks, 6 weeks and 3 months after surgery</time_frame>
    <description>cumulative amount of opioids administered during the time frame</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Fracture of Shoulder and Upper Arm</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CISB control for A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One time injection of 1.3% Liposomal Bupivacaine during Humerus Fracture Fixation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CISB control for B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peripheral nerve block (CISB) with 0.125% bupivacaine during fracture fixation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.3% Liposomal Bupivacaine</intervention_name>
    <description>local tissue infiltration of Liposomal Bupivacaine during surgery</description>
    <arm_group_label>Liposomal Bupivacaine A</arm_group_label>
    <arm_group_label>Liposomal Bupivacaine B</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.125% Bupivacaine</intervention_name>
    <description>Continues nerve block with Bupivacaine during surgery and postoperatively</description>
    <arm_group_label>CISB control for A</arm_group_label>
    <arm_group_label>CISB control for B</arm_group_label>
    <other_name>Bupivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing shoulder arthroplasty under general anesthesia

          -  Patients undergoing open reduction internal fixation (ORIF) of a proximal humerus
             fracture under general anesthesia

          -  Patients with American Society of Anesthesiologist (ASA) physical status
             classification of 1-3

          -  Patients meeting criteria for standard of care continuous peripheral nerve block
             (CPNB) per anesthesia guidelines.

          -  Patients agreeing to be available for brief follow up telephone survey post-
             operatively and being mentally able to respond.

          -  Patients available for follow up routine post-operative clinic visits, per standard
             of care.

        Exclusion Criteria:

          -  Contraindications to regional anesthesia

          -  Significant peripheral neuropathy or neurological disorder affecting the upper
             extremity

          -  Contraindication to a component of multimodal analgesia

          -  Pregnancy

          -  Opioid tolerance

          -  Cognitive or psychiatric condition that might affect patient assessment and/or
             inability to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wayne State University Physician Group</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 27, 2016</lastchanged_date>
  <firstreceived_date>June 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Vani J. Sabesan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Shoulder Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
